The estimated Net Worth of Geert R Kersten is at least $5.96 Milion dollars as of 8 May 2024. Mr. Kersten owns over 30,000 units of Cel-Sci stock worth over $1,410,465 and over the last 21 years he sold CVM stock worth over $0. In addition, he makes $4,546,360 as Chief Executive Officer, Treasurer oraz Director at Cel-Sci.
Sign up
Mr. Kersten CVM stock SEC Form 4 insiders trading
Geert has made over 29 trades of the Cel-Sci stock since 2003, according to the Form 4 filled with the SEC. Most recently he bought 30,000 units of CVM stock worth $41,700 on 8 May 2024.
The largest trade he's ever made was buying 348,125 units of Cel-Sci stock on 26 March 2013 worth over $73,106. On average, Geert trades about 8,900 units every 45 days since 2003. As of 8 May 2024 he still owns at least 1,195,309 units of Cel-Sci stock.
You can see the complete history of Mr. Kersten stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Geert Kersten biography
Geert R. Kersten Esq. serves as Chief Executive Officer, Treasurer, Director of the Company. Geert Kersten has served in his current leadership role at CEL-SCI since 1995. Mr. Kersten has been with CEL-SCI since 1987. He has been involved in the pioneering field of cancer immunotherapy for over three decades and has successfully steered CEL-SCI through many challenging cycles in the biotechnology industry. Mr. Kersten also provides CEL-SCI with significant expertise in the fields of finance and law and has a unique vision of how CEL-SCI's Multikine product could potentially change the way cancer is treated. Prior to joining CEL-SCI, Mr. Kersten worked at the law firm of Finley & Kumble and worked at Source Capital, an investment banking firm located in McLean, VA. He is a native of Germany, graduated from high school in England, and completed his studies in the US. Mr. Kersten received his Undergraduate Degree in Accounting and an M.B.A. from George Washington University, and a law degree (J.D.) from American University in Washington, DC. Mr. Kersten’s experience overseeing the financing and research and development of CEL-SCI for over 25 years qualifies him to continue to serve on CEL-SCI’s board of directors. Mr. Kersten is also the inventor of a patent on the potential use of Multikine® (Leukocyte Interleukin, Injection) in managing cholesterol.
What is the salary of Geert Kersten?
As the Chief Executive Officer, Treasurer oraz Director of Cel-Sci, the total compensation of Geert Kersten at Cel-Sci is $4,546,360. There are no executives at Cel-Sci getting paid more.
How old is Geert Kersten?
Geert Kersten is 61, he's been the Chief Executive Officer, Treasurer oraz Director of Cel-Sci since 1995. There are 13 older and no younger executives at Cel-Sci. The oldest executive at Cel-Sci Corp. is Dr. Daniel H. Zimmerman Ph.D., 80, who is the Sr. VP of Research & Cellular Immunology.
What's Geert Kersten's mailing address?
Geert's mailing address filed with the SEC is 8229 BOONE BLVD, STE 802, VIENNA, VA, 22182.
Insiders trading at Cel-Sci
Over the last 21 years, insiders at Cel-Sci have traded over $3,069,559 worth of Cel-Sci stock and bought 1,693,350 units worth $1,328,136 . The most active insiders traders include Clara Maximilian De, Geert R Kersten oraz Eyal Talor. On average, Cel-Sci executives and independent directors trade stock every 50 days with the average trade being worth of $42,938. The most recent stock trade was executed by Robert Eugene Watson on 8 May 2024, trading 20,000 units of CVM stock currently worth $27,800.
What does Cel-Sci do?
cel-sci corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. the company's lead investigational immunotherapy is multikine, which is under phase iii clinical trial for the treatment of head and neck cancer. its ligand epitope antigen presentation system (leaps), a pre-clinical patented t-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. the company also develops leaps-h1n1-dc; cel-2000 and cel-4000 are product candidates for the treatment of rheumatoid arthritis; and leaps cov-19, a product candidate to treat covid-19 coronavirus. cel-sci corporation has a collaboration agreement with the university of georgia's center for vaccines and immunology to develop leaps covid-19 immunotherapy. the company was founded in 1983 and is headquartered in vienna, virginia.
What does Cel-Sci's logo look like?
Complete history of Mr. Kersten stock trades at Cel-Sci
Cel-Sci executives and stock owners
Cel-Sci executives and other stock owners filed with the SEC include:
-
Geert Kersten,
Chief Executive Officer, Treasurer, Director -
Patricia Prichep,
Senior Vice President - Operations, Corporate Secretary -
Eyal Talor,
Chief Scientific Officer -
Daniel Zimmerman,
Senior Vice President - Research, Cellular Immunology -
John Cipriano,
Senior Vice President - Regulatory Affairs -
Peter Young,
Independent Director -
Robert Watson,
Independent Director -
Bruno Baillavoine,
Independent Director -
Geert R. Kersten,
CEO, Principal Accounting & Financial Officer, Treasurer and Director -
Geert R. Kersten Esq.,
Chief Exec. & Financial Officer, Treasurer and Director -
Dr. Eyal Talor Ph.D.,
Chief Scientific Officer -
Patricia B. Prichep,
Sr. VP of Operations & Corp. Sec. -
Dr. Daniel H. Zimmerman Ph.D.,
Sr. VP of Research & Cellular Immunology -
John Cipriano,
Sr. VP of Regulatory Affairs -
Clara Maximilian De,
President -
Alexander G Esterhazy,
Director -
C Richard Kinsolving,
Director -
Gail K Naughton,
Director